Alpha Pharmaceuticals is pioneering the next generation of non-invasive diagnostics and novel therapeutics. We detect what others miss—and treat what others can't.
Alpha Pharmaceuticals: DNA looks at the past, RNA looks into the future.
Utilizing proprietary enrichment of microRNA (miRNA) and circular RNA (circRNA) to detect disease earlier than ever before.
Traditional liquid biopsies (cfDNA) struggle to detect "fusion" events and low-shedding tumors, particularly in pediatric cancers like Ewings Sarcoma and Neuroblastoma.
Our platform uses circRNA and miRNA, which are more stable and abundant than DNA. This allows us to detect fusion genes with unprecedented sensitivity.
Targeting the $30B+ Liquid Biopsy Market, specifically addressing the gap in pediatric and fusion-driven cancer diagnostics.
High maternal BMI frequently leads to "No Call" results in standard NIPT due to low fetal fraction (DNA dilution).
Reliable prenatal screening for all expectant mothers, regardless of body mass index (BMI), ensuring equitable care.
Unlike cfDNA, our miRNA/circRNA markers are independent of fetal fraction. This delivers robust results for aneuploidies even in high BMI pregnancies where other tests fail.
Disrupting the $13B+ Global NIPT Market by capturing the significant segment of "failed calls" and difficult cases.
Current diagnosis relies on behavioral observation, often delaying confirmation until age 3 or 4.
Early Intervention Window
A biological, objective screen for Autism Spectrum Disorder to enable earlier intervention and better outcomes.
A multi-analyte miRNA panel identified in peripheral blood that correlates with neurodevelopmental markers, detectable as early as 18 months.
Addressing the rapid rise in ASD prevalence (1 in 36 children) within the global Pediatric Diagnostics Market.
Repurposed assets and novel formulations for rapid regulatory pathways.
True biological reversal of cellular aging, not just cosmetic masking.
A patent-pending topical formulation using a repurposed FDA-approved drug that blocks telomerase shortening, effectively extending cell lifespan.
$60B+ Global Anti-Aging Market
Effective hair restoration without the systemic side effects of oral medications.
A patent-pending Mesotherapy Formulation that delivers active compounds directly to the follicle, bypassing systemic barriers.
$12B+ Hair Loss Market
Treatment for resistant fungal ear infections where current therapeutic options are limited.
A novel antifungal formulation with a targeted delivery system designed to penetrate difficult biofilms.
High-Unmet Need ENT Niche
| Program | Indication | Technology | Status |
|---|---|---|---|
| APCI-001 | Oncology (Liquid Biopsy) | circRNA / miRNA Fusion Detection | Patent Pending |
| APCI-002 | Autism (ASD) Screening | miRNA Panel | Patent Pending |
| APCI-003 | Dermal Anti-Aging | Telomerase Modulator (Repurposed) | Patent Pending |
| APCI-004 | Alopecia (Hair Loss) | Mesotherapy Formulation | Patent Pending |
| APCI-005 | Fungal Otitis Externa | Novel Antifungal Delivery | Patent Submitted |
Alpha Pharmaceuticals International Corporation operates on a "Platform-as-a-Service" model. We are currently initiating a Series A round of $15 Million dedicated to the clinical validation of our proprietary RNA patent portfolio and commercial acceleration.
Use of Funds
Clinical validation of Oncology & ASD assets; Regulatory filing for therapeutics.
Investment Vehicle
Series A Equity Round (Open to Institutional & Accredited Investors).